313 - Genomic Features Associated with Non-susceptibility to Cefiderocol in Pseudomonas aeruginosa and Cross-resistance to Novel β-lactam/β-lactamase Inhibitors in the Prospective Observational Pseudomonas (POP) study

Friday, October 18, 2024

11:06 AM – 11:18 AM US PT

Location: 404 AB

Presenting Author(s)

SE

Stephanie L. Egge, MD

Assistant Professor
Oregon Health & Science University
Portland, OR, United States

Slides

Co-Author(s)

PT

Phillip C. Thornton, BS

Houston Methodist Research Institute
Houston, Texas, United States
EF

Erika Flores, PhD

Houston Methodist Research Institute
Houston, Texas, United States
Rd

Rodrigo de Paula Baptista, PhD

Houston Methodist Hospital
Houston, Texas, United States
KC

Karim Clarke, N/A

Southwestern University
Georgetown, Texas, United States
Cesar A. Arias, MD, MSc, PhD (he/him/his)

Professor and Chief
Houston Methodist and Weill Cornell Medical College
Houston, TX, United States
Vincent Tam, Pharm. D.

Professor
University of Houston
Houston, TX, United States
Michael J. Satlin, MD

Associate Professor
Weill Cornell Medicine
New York, NY, United States
William R. Miller, M.D.

Assistant Professor
Houston Methodist Research Institute
Houston, TX, United States

Disclosure(s):

Stephanie L. Egge, MD: No financial relationships to disclose

Phillip C. Thornton, BS: No financial relationships to disclose

Erika Flores, PhD: No financial relationships to disclose

Rodrigo de Paula Baptista, PhD: No financial relationships to disclose

Karim Clarke, N/A: No financial relationships to disclose

Cesar A. Arias, MD, MSc, PhD: UpToDate, Inc.: Royalties

Vincent Tam, Pharm. D.: AbbVie Inc: Advisor/Consultant (Terminated, June 14, 2024)

Michael J. Satlin, MD: AbbVie: DSMB participant; bioMerieux: Grant/Research Support; Merck: Grant/Research Support; Selux Diagnostics: Grant/Research Support; SNIPRBiome: Grant/Research Support

William R. Miller, M.D.: Merck: Grant/Research Support; UptoDate: Royalties